Italian Network MDS Registry
FISM_registry
Rete Italiana Dei Registri Regionali Delle Sindromi Mielodisplastiche (MDS)
1 other identifier
observational
10,000
1 country
20
Brief Summary
Epidemiological data collection of adult patients affected by myelodysplastic syndrome (MDS) newly diagnosed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2013
Longer than P75 for all trials
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedFirst Submitted
Initial submission to the registry
May 18, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2016
CompletedFirst Posted
Study publicly available on registry
June 22, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2032
ExpectedMarch 4, 2025
February 1, 2025
2.8 years
May 18, 2016
February 27, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Incidence of MDS diagnosis
Number of new cases every 100.000 person/year
6 years
Overall Response rate
Proportion of CR or PR after each line of treatment in term of erythroid, platelet and granulocyte response
6 years
Prevalence of MDS
Number of cases every 100.000 person
6 years
Overall survival
Time between MDS diagnosis and death due to any causes
6 years
Progression free survival
Time between MDS diagnosis and relapse/ progression or death due to any causes
6 years
Progression to AML
Time between MDS diagnosis and Progression to AML or death due to any causes
6 years
Eligibility Criteria
Patient with new diagnosis of MDS
You may qualify if:
- New diagnosis of MDS
You may not qualify if:
- Patient who refuse the signature of informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Ematologia, AO SS. Antonio e Biagio
Alessandria, AL, 15121, Italy
Clinica di Ematologia, AOU Ospedale di Torrette
Ancona, AN, 60020, Italy
U.O. Clinica Medicina Interna, IRCCS San Martino IST
Genova, GE, 16132, Italy
Struttura Cattedra di Ematologia e CTMO, AOU di Parma
Parma, PR, 43100, Italy
Ematologia e Centro Trapianti, Centro di Riferimento Oncologico della Basilicata
Rionero in Vulture, PZ, 85028, Italy
FPO - IRCCS di Candiolo
Candiolo, Torino, 10060, Italy
S.C.D.U. Ematologia e Terapie cellulari, Ospedale Mauriziano
Torino, TO, 10128, Italy
Ospedale Cardinal Massaia
Asti, Italy
Ematologia AOU Policlinico di Bari
Bari, 70124, Italy
Istituto di Ematologia e Oncologia Medica, Policlinico S.Orsola
Bologna, 40100, Italy
Ematologia- Ospedale Businco
Cagliari, 09121, Italy
Ospedale Maggiore
Chieri, Italy
Cattedra di Ematologia Policlino Careggi
Florence, 50134, Italy
Dipartimento Emato-Oncologia AOU San Martino Genova
Genova, 16132, Italy
Medicina interna II Divisione di Ematologia Ospedale S.Luigi Gonzaga
Orbassano, 10043, Italy
Azienda Ospedaliera di Padova
Padua, 35128, Italy
Azienda Ospedaliera Perugia
Perugia, Italy
AOU San Salvatore
Pesaro, 61122, Italy
Ospedale San Giovanbni Battista-Molinette
Torino, Italy
Divisione di Ematologia-Ospedale Cardinale Panico
Tricase, 73039, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 18, 2016
First Posted
June 22, 2016
Study Start
September 1, 2013
Primary Completion
June 1, 2016
Study Completion (Estimated)
May 1, 2032
Last Updated
March 4, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share